GSK Hycamtin cervical cancer sNDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's sNDA for use of its topoisomerase inhibitor Hycamtin (topotecan) in combination with cisplatin for second-line treatment of recurrent or persistent cervical cancer will receive a priority review, the firm announces Feb. 17. The application has a June 15 action date. The sNDA is based on a single Phase III study of 147 women treated with Hycamtin plus cisplatin compared with 146 patients on cisplatin alone. The trial found a statistically significant improvement in median overall survival of 9.4 months for Hycamtin/cisplatin versus 6.5 months for cisplatin alone...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.